You are here

Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Athens, , 11526 Greece
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Epilepsy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Outpatients equal to or greater than 18 years of age with diagnosis of epilepsy with
partial seizures having minimum of two partial seizures during a two month period
before the baseline visit

- Having a clinical history of epilepsy and AED treatment at least 1 year prior to
inclusion

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- AED or Seizures/Epilepsy Related Exclusions:having a treatable cause of seizures

- Having absences seizures

- Having had status epileptics within the year prior to inclusion

- Having a progressive neurological or systematic disorder

- Having known significant renal or hepatic dysfunction

NCT00288639
Pfizer
Completed
Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now